Zobrazeno 1 - 10
of 810
pro vyhledávání: '"Gert Van Assche"'
Autor:
Richard B. Gearry, Andrew M. McCombie, Morten Vatn, David T. Rubin, Flavio Steinwurz, Edward V. Loftus, Wolfgang Kruis, Curt Tysk, Jean-Frederic Colombel, Siew C. Ng, Gert Van Assche, Charles N. Bernstein
Publikováno v:
Inflammatory Intestinal Diseases, Pp 1-9 (2021)
Background and Aims: As inflammatory bowel disease (IBD) becomes more prevalent, the challenges that gastroenterologists face in managing these patients evolve. We aimed to describe the most important challenges facing gastroenterologists from around
Externí odkaz:
https://doaj.org/article/08e0986bcf6a49e4b3696e102164a819
Autor:
Brecht Creyns, Jonathan Cremer, Gert De Hertogh, Louis Boon, Marc Ferrante, Séverine Vermeire, Gert Van Assche, Jan L. Ceuppens, Christine Breynaert
Publikováno v:
Immunity, Inflammation and Disease, Vol 8, Iss 3, Pp 393-407 (2020)
Abstract Introduction Insight in the pathogenesis of intestinal fibrosis is an unmet medical need in inflammatory bowel diseases. Studies in murine models and human organ fibrosis point to a potential role of innate lymphoid cells (ILC) in chronic in
Externí odkaz:
https://doaj.org/article/5d6cdb7792ed41ffaf8b40ff3704f4f5
Autor:
Heinfried H. Radeke, Jürgen Stein, Gert Van Assche, Gerhard Rogler, Peter L. Lakatos, Florian Muellershausen, Pierre Moulin, Philip Jarvis, Laurence Colin, Peter Gergely, Wolfgang Kruis
Publikováno v:
Inflammatory Intestinal Diseases, Pp 1-11 (2020)
Background and Aims: KRP203 is a potent oral agonist of the sphingosine-1-phosphate receptor subtype 1 that induces the sequestration of peripheral lymphocytes, thereby potentially reducing the number of activated lymphocytes circulating to the gastr
Externí odkaz:
https://doaj.org/article/b2995644ed9f4c96bffe9657f67e3707
Autor:
Bram Verstockt, Sare Verstockt, Jonas Dehairs, Vera Ballet, Helene Blevi, Willem-Jan Wollants, Christine Breynaert, Gert Van Assche, Séverine Vermeire, Marc Ferrante
Publikováno v:
EBioMedicine, Vol 40, Iss , Pp 733-742 (2019)
Background: With the changed therapeutic armamentarium for Crohn's disease (CD) and ulcerative colitis (UC), biomarkers predicting treatment response are urgently needed. We studied whole blood and mucosal expression of genes previously reported to p
Externí odkaz:
https://doaj.org/article/87319cf6791e492abe7f1401486b25e3
Autor:
Brecht Creyns, Inge Jacobs, Bram Verstockt, Jonathan Cremer, Vera Ballet, Roselien Vandecasteele, Tim Vanuytsel, Marc Ferrante, Séverine Vermeire, Gert Van Assche, Jan L. Ceuppens, Christine Breynaert
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Patients with Crohn disease (CD) and ulcerative colitis (UC) suffer from chronic relapsing intestinal inflammation. While many studies focused on adaptive immunity, less is known about the role of innate immune cells in these diseases. Innate lymphoi
Externí odkaz:
https://doaj.org/article/1fbaaa909c7142f699d64bb2437bacaf
Autor:
Silvio Danese, Rupa Banerjee, JR Fraser Cummings, Iris Dotan, Paulo G Kotze, Rupert Wing Loong Leong, Kristine Paridaens, Laurent Peyrin-Biroulet, Glyn Scott, Gert Van Assche, Jan Wehkamp, Jesús K Yamamoto-Furusho
Publikováno v:
Intestinal Research, Vol 16, Iss 4, Pp 522-528 (2018)
Symptomatic ulcerative colitis (UC) can be a chronic, disabling condition. Flares in disease activity are associated with many of the negative impacts of mild-to-moderate UC. Rapid resolution of flares can provide benefits to patients and healthcare
Externí odkaz:
https://doaj.org/article/c5c9bafdb482423aaf5c56a8aa60cdab
Autor:
Magali de Bruyn, Christine Breynaert, Ingrid Arijs, Gert De Hertogh, Karel Geboes, Greet Thijs, Gianluca Matteoli, Jialiang Hu, Jo Van Damme, Bernd Arnold, Marc Ferrante, Séverine Vermeire, Gert Van Assche, Ghislain Opdenakker
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-15 (2017)
Metalloproteinase-9 has been suggested as therapeutic target to treat inflammatory bowel disease. Here de Bruynet al. show that genetic and pharmacological inhibition of metalloproteinase-9 does not ameliorate inflammation and fibrosis in mice challe
Externí odkaz:
https://doaj.org/article/cf83337903164ea1a97bfb338b28091a
Autor:
Isabelle Cleynen, Loes Linsen, Sare Verstockt, Bram Verstockt, Vera Ballet, Eline Vandeput, Gert Van Assche, Marc Ferrante, Kristel Van Landuyt, Séverine Vermeire, Nadine Ectors
Publikováno v:
Frontiers in Medicine, Vol 6 (2019)
Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory condition affecting mainly the gastro-intestinal tract with two main entities: Crohn's disease (CD) and ulcerative colitis (UC). Although the exact mechanisms underlying the initial
Externí odkaz:
https://doaj.org/article/dbc7c9b8d18f41bf923ab7a46150581d
Autor:
Bram Verstockt, Clémentine Perrier, Gert De Hertogh, Jonathan Cremer, Brecht Creyns, Gert Van Assche, Marc Ferrante, Jan L. Ceuppens, Séverine Vermeire, Christine Breynaert
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Background: Mucosal IL-13 Receptor alpha 2 (IL13RA2) mRNA expression is one of the best predictive markers for primary non-responsiveness to infliximab therapy in patients with inflammatory bowel disease (IBD). The objective of this study was to unde
Externí odkaz:
https://doaj.org/article/d9d49cafa599439a8d6fd6e6d6a1a949
Autor:
Gert Van Assche, Axel U. Dignass, Britta Siegmund, William J. Sandborn, Laurent Peyrin-Biroulet, James O. Lindsay, Iris Dotan
Publikováno v:
European Medical Journal Gastroenterology, Vol 4, Iss 1, Pp 40-49 (2015)
Despite major advances in the inflammatory bowel disease (IBD) treatment landscape, the management of ulcerative colitis (UC) and Crohn’s disease (CD) continues to pose challenges. There is significant scope to optimise treatment of IBD, and conven
Externí odkaz:
https://doaj.org/article/9897d92318654ba5b09492bfd373296a